Higher Frequency Zoledronic Acid in the Treatment of Multiple Myeloma (dtZ)
An International, Multicenter, Non-Randomized, Open-Labeled Study to Evaluate the Efficacy of Lower Dose Dexamethasone/Thalidomide and Higher Frequency ZOMETA(TM) in the Treatment of Previously Untreated Patients With Multiple Myeloma
Sponsor: Asan Medical Center
This PHASE2 trial investigates Multiple Myeloma and is currently completed. Asan Medical Center leads this study, which shows 6 recorded versions since 2005 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE2
First recorded
Dec 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Asan Medical Center
- Chonnam National University Hospital
- Christian Medical College, Vellore, India
- Gleneagles Hospital
- National Cancer Centre, Singapore
- Samsung Medical Center
- Seoul National University Hospital
- Singapore General Hospital
- Tan Tock Seng Hospital
- Tata Memorial Hospital
For direct contact, visit the study record on ClinicalTrials.gov .